-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Wind data shows that in 2021, a total of 2,002 A-share listed companies received 5,442 institutional surveys, an increase of more than 400 companies compared with the same period in 2020
.
Judging from the number of surveys, 11 companies will receive more than 1,000 intensive surveys in 2021.
In addition, 67 companies will have 500 reception agencies, and 509 companies will have 100 reception agencies
.
From the perspective of industries intensively researched by institutions, they mainly focus on industries such as electronics, pharmaceutical biology, machinery and equipment, and chemical industry
.
Among them, among the 11 companies that have received more than 1,000 intensive investigations in 2021, the domestic medical equipment giant Mindray Medical has been "crossed the threshold", and has received 10 batches of institutional investigations, with a total of 2,102, becoming the first company to break through 2,000.
home company
.
According to the data, Mindray Medical's main products cover the three major fields of life information and support, in vitro diagnosis and medical imaging.
It has a very complete product line in the same industry in China.
The program meets clinical needs
.
After 30 years of development, Mindray Medical's three core businesses have not only seized dividends in the medical device market, but also possessed sufficient international competitiveness.
In addition, in recent years, the company has also targeted emerging emerging markets such as minimally invasive surgery, animal medicine, and orthopedics.
field strength
.
In the first three quarters of 2021, Mindray Medical achieved a main income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; net profit attributable to the parent was 6.
663 billion yuan, a year-on-year increase of 24.
23%; deducted non-net profit of 6.
544 billion yuan, a year-on-year increase of 24.
3%
.
In terms of R&D investment, Mindray Medical has always been a high investment
.
From 2018 to 2020, Mindray Medical's total R&D investment was 1.
42 billion yuan, 1.
649 billion yuan, and 2.
096 billion yuan, accounting for 10.
33%, 9.
96%, and 9.
97% of its operating income, respectively
.
In the first three quarters of 2021, the company's R&D investment reached 1.
79 billion yuan, a year-on-year increase of about 19%, and R&D investment accounted for 9.
23%
.
On January 4th, Mindray Medical released a record sheet of survey activities received by a total of 649 institutions from October to December 2021.
From the perspective of the research content, the institutions are mainly concerned about the core competitiveness of Haipeptide Biology and the technology of newly launched products.
Features, overseas market conditions, and the impact of the implementation of the DRG/DIP payment method reform on the company
.
At the end of 2021, Mindray Medical announced that it would acquire 100% of the equity of the large-scale machinery company Haiti Biological and its subsidiaries for 4 billion yuan.
This news has attracted much attention from the industry and institutions
.
In this regard, Mindray Medical said that compared with other suppliers, Haipeptide Bio has unique core competitiveness in many aspects.
Among them, the team of scientists and the product development process built on basic scientific research are the core and unique.
The development process of protein is a typical case
.
At the same time, from an industrial point of view, Haiti can meet customer needs, including value-added, guarantee and cost reduction
.
In addition, through continuous R&D investment, the Haipeptide R&D team has also accumulated a wide technical pool and has the ability to develop high-quality antigens
.
Mindray Medical believes that the competitiveness of Haiti Bio is comprehensive.
The company will firmly support Haiti Bio to continuously increase R&D investment, strengthen technological innovation and academic exploration of raw materials, and make solid contributions to the early realization of global development of Mindray's in vitro diagnostic business.
strength
.
.
Judging from the number of surveys, 11 companies will receive more than 1,000 intensive surveys in 2021.
In addition, 67 companies will have 500 reception agencies, and 509 companies will have 100 reception agencies
.
From the perspective of industries intensively researched by institutions, they mainly focus on industries such as electronics, pharmaceutical biology, machinery and equipment, and chemical industry
.
Among them, among the 11 companies that have received more than 1,000 intensive investigations in 2021, the domestic medical equipment giant Mindray Medical has been "crossed the threshold", and has received 10 batches of institutional investigations, with a total of 2,102, becoming the first company to break through 2,000.
home company
.
According to the data, Mindray Medical's main products cover the three major fields of life information and support, in vitro diagnosis and medical imaging.
It has a very complete product line in the same industry in China.
The program meets clinical needs
.
After 30 years of development, Mindray Medical's three core businesses have not only seized dividends in the medical device market, but also possessed sufficient international competitiveness.
In addition, in recent years, the company has also targeted emerging emerging markets such as minimally invasive surgery, animal medicine, and orthopedics.
field strength
.
In the first three quarters of 2021, Mindray Medical achieved a main income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; net profit attributable to the parent was 6.
663 billion yuan, a year-on-year increase of 24.
23%; deducted non-net profit of 6.
544 billion yuan, a year-on-year increase of 24.
3%
.
In terms of R&D investment, Mindray Medical has always been a high investment
.
From 2018 to 2020, Mindray Medical's total R&D investment was 1.
42 billion yuan, 1.
649 billion yuan, and 2.
096 billion yuan, accounting for 10.
33%, 9.
96%, and 9.
97% of its operating income, respectively
.
In the first three quarters of 2021, the company's R&D investment reached 1.
79 billion yuan, a year-on-year increase of about 19%, and R&D investment accounted for 9.
23%
.
On January 4th, Mindray Medical released a record sheet of survey activities received by a total of 649 institutions from October to December 2021.
From the perspective of the research content, the institutions are mainly concerned about the core competitiveness of Haipeptide Biology and the technology of newly launched products.
Features, overseas market conditions, and the impact of the implementation of the DRG/DIP payment method reform on the company
.
At the end of 2021, Mindray Medical announced that it would acquire 100% of the equity of the large-scale machinery company Haiti Biological and its subsidiaries for 4 billion yuan.
This news has attracted much attention from the industry and institutions
.
In this regard, Mindray Medical said that compared with other suppliers, Haipeptide Bio has unique core competitiveness in many aspects.
Among them, the team of scientists and the product development process built on basic scientific research are the core and unique.
The development process of protein is a typical case
.
At the same time, from an industrial point of view, Haiti can meet customer needs, including value-added, guarantee and cost reduction
.
In addition, through continuous R&D investment, the Haipeptide R&D team has also accumulated a wide technical pool and has the ability to develop high-quality antigens
.
Mindray Medical believes that the competitiveness of Haiti Bio is comprehensive.
The company will firmly support Haiti Bio to continuously increase R&D investment, strengthen technological innovation and academic exploration of raw materials, and make solid contributions to the early realization of global development of Mindray's in vitro diagnostic business.
strength
.
